This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kaplan, M. A. Articles by Nelson, E. B. Search for Related Content PubMed PubMed Citation Articles by Kaplan, M. A. Articles by Nelson, E. B. Social Bookmarking                         What's this?

A Multicenter Randomized Controlled Trial of a Liquid Loperamide Product Versus Placebo in the Treatment of Acute Diarrhea in Children

Mary Jane Prior, PhD, MPH

Kimberly I. McKonly, MS

Medical Department, McNeil Consumer Healthcare, 7050 Camp Hill Road, Fort Washington, PA

Herbert L. DuPont, MD

Internal Medicine, St. Luke's Episcopal Hospital, Houston, TX

Anthony R. Temple, MD

Edward B. Nelson, MD, PhD

Medical Department, McNeil Consumer Healthcare, 7050 Camp Hill Road, Fort Washington, PA

This randomized, double-blind, placebo-controlled trial of 48 hours' duration conducted in 13 primary care ambulatory practices in the United States and Mexico was used to compare the efficacy and safety of loperamide with placebo for the treatment of acute diarrhea in children aged 2 through 11 years. Two hundred fifty-eight children with acute nonspecific diarrhea were enrolled. Children were randomly assigned to treatment with loperamide HCO 0.5 mg/5 mL (n= 130) or placebo (n=1 28). The first dose of loperamide consisted of either 1.0 mg (children 2 through 5 years of age) or 2.0 mg (children 6 through 11 years of age) of study medication under the observation of study personnel. This was followed by 1 mg after each unformed stool, with a total daily dose of up to 3.0 mg in the children 2-5 years of age, 4.0 mg in the children 6-8 years of age, and 6.0 mg in the children 9-11 years of age. The primary outcome measures were time to last unformed stool, time to first unformed stool, number of unformed stools during six consecutive 8-hour periods, and overall rating of efficacy/acceptability. Secondary outcomes included abdominal pain/cramping, vomiting, and fever. Children who received loperamide had significantly shorter time to last unformed stool (p=0.001⁷) and fewer numbers of unformed stools (p=0.0237) than children who received placebo. The end-of-study overall efficacy/acceptability rating of loperamide was significantly better than for placebo (p=0.010⁷). All other clinically important outcome measures related to diarrhea relief favored loperamide. There was no significant difference in the incidence of drug-related adverse events between treatment groups, although total adverse events were reported more frequently (p=O.048) by the loperamide group (15%) compared with the placebo group (7%). In conclusion, this controlled study provides data demonstrating that at recommend doses, loperamide is well tolerated and significantly shortens the duration and severity of symptoms of acute nonspecific diarrhea in children 2 through 11 years of age.

Clinical Pediatrics, Vol. 38, No. 10, 579-591 (1999)
DOI: 10.1177/000992289903801003


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. K. Orr, K. L. Matson, and B. J. Cowles Nonprescription Medication Use by Infants and Children: Product Labeling Versus Evidence-Based Medicine Journal of Pharmacy Practice, October 1, 2006; 19(5): 286 - 294. [Abstract] [PDF]

				A C Casburn-Jones and M J G Farthing Management of infectious diarrhoea Gut, February 1, 2004; 53(2): 296 - 305. [Full Text] [PDF]